μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia | Synapse
March 3, 2026
μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia
Puntos clave
Single-cell drug sensitivity predictions highlight significant variability in responses among leukemia cells, indicating some are more resistant to treatment.
The method delivers predictions with over 85% accuracy based on AI algorithms applied to analyses of cell responses to various drugs.
Using a microfluidic approach, the platform enables the assessment of thousands of individual cells under controlled conditions for novel insights.
Findings may enhance personalized medicine efforts for leukemia, indicating tailored treatments could improve outcomes significantly.